• PDF / 170,959 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 9 Downloads / 163 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 3 case reports In a retrospective study of 20 paediatric patients, who underwent heart transplant between January 2016 and June 2019 in India, three patients (2 boys and 1 girl) aged 4.5–14.6 years were described, who developed sternal infection and unspecified bacterial infection (one patient), Escherichia coli infection of the urinary tract and pancreatitis (one patient) or died due to antibody mediated rejection following treatment failure during treatment with basiliximab, methylprednisolone, mycophenolate mofetil, prednisolone, tacrolimus or rosuvastatin [not all dosages and routes stated]. The 14.6-year-old boy (patient 5, table no 1), who had dilated cardiomyopathy, presented for heart transplantation. Immunosuppression was inducted with IV basiliximab 10mg and methylprednisolone 30 mg/kg. He also received epinephrine [adrenaline], milrinone and fentanyl. Orthotopic heart transplant was performed. Post-operatively, immunosuppression was maintained with tacrolimus 0.5mg twice a day (started on post-transplant day 4), mycophenolate mofetil 20 mg/kg/dose twice a day (started on post-operative day 1) and prednisolone for the first 12 months after the transplant. Rosuvastatin was added to prevent hyperlipidaemia. Subsequently, the treatment failed. He developed acute grade 2 antibody mediated heart transplant rejection, and died. The 11.1-year-old boy (patient 10, table no 1), who had restricted cardiomyopathy, presented for heart transplantation. Immunosuppression was inducted with IV basiliximab 10mg and methylprednisolone 30 mg/kg. He also received epinephrine [adrenaline], milrinone and fentanyl. Orthotopic heart transplant was performed. Post-operatively, immunosuppression was maintained with tacrolimus 0.5mg twice a day (started on post-transplant day 4), mycophenolate mofetil 20 mg/kg/dose twice a day (started on post-operative day 1) and prednisolone for the first 12 months after the transplant. Rosuvastatin was added to prevent hyperlipidaemia. Subsequently, he developed unspecified bacterial infection, which was successfully treated with unspecified antibiotics. He also developed sternal infection. He later developed B-cell myeloproliferative disorder [aetiology not specified], which was successfully treated with modifying immunosuppressant drug therapy with rituximab. The 4.5-year-old girl (patient 12, table no 1), who had dilated cardiomyopathy, presented for heart transplantation. Immunosuppression was inducted with IV basiliximab 10mg and methylprednisolone 30 mg/kg. She also received epinephrine [adrenaline], milrinone and fentanyl. Orthotopic heart transplant was performed. Post-operatively, immunosuppression was maintained with tacrolimus 0.5mg twice a day (started on post-transplant day 4), mycophenolate mofetil 20 mg/kg/dose twice a day (started on post-operative day 1) and prednisolone for the first 12 months after the transplant. Rosuvastatin was added to prevent hyperlipidaemia. Within the first three months post-transplant, she developed urinary tract infection. Uri